These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20882878)

  • 1. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer.
    Candelaria M; Cetina L; Pérez-Cárdenas E; de la Cruz-Hernández E; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Chanona J; Arias D; Dueñas-González A
    Eur J Gynaecol Oncol; 2010; 31(4):386-91. PubMed ID: 20882878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
    Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
    Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
    Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
    Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation.
    Dueñas-Gonzalez A; López-Graniel C; González-Enciso A; Cetina L; Rivera L; Mariscal I; Montalvo G; Gómez E; de la Garza J; Chanona G; Mohar A
    Ann Oncol; 2003 Aug; 14(8):1278-84. PubMed ID: 12881393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.
    Tharavichitkul E; Lorvidhaya V; Kamnerdsupaphon P; Sukthomya V; Chakrabandhu S; Klunklin P; Onchan W; Supawongwattana B; Pukanhaphan N; Galalae R; Chitapanarux I
    BMC Cancer; 2016 Jul; 16():501. PubMed ID: 27435245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma.
    Duenas-Gonzalez A; Cetina L; Sánchez B; Gomez E; Rivera L; Hinojosa J; López-Graniel C; Gonzalez-Enciso A; de la Garza J
    Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1361-5. PubMed ID: 12873681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
    Coronel J; Cetina L; Pacheco I; Trejo-Becerril C; González-Fierro A; de la Cruz-Hernandez E; Perez-Cardenas E; Taja-Chayeb L; Arias-Bofill D; Candelaria M; Vidal S; Dueñas-González A
    Med Oncol; 2011 Dec; 28 Suppl 1():S540-6. PubMed ID: 20931299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended field radiation and cisplatin for stage IIB and IIIB cervical carcinoma.
    Malfetano JH; Keys H; Cunningham MJ; Gibbons S; Ambros R
    Gynecol Oncol; 1997 Nov; 67(2):203-7. PubMed ID: 9367709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects.
    King M; McConkey C; Latief TN; Hartley A; Fernando I
    Clin Oncol (R Coll Radiol); 2006 Feb; 18(1):38-45. PubMed ID: 16477918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.
    Castelnau-Marchand P; Chargari C; Maroun P; Dumas I; Del Campo ER; Cao K; Petit C; Martinetti F; Tafo-Guemnie A; Lefkopoulos D; Morice P; Haie-Meder C; Mazeron R
    Gynecol Oncol; 2015 Nov; 139(2):288-94. PubMed ID: 26364808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix.
    Uno T; Mitsuhashi A; Isobe K; Yamamoto S; Kawakami H; Ueno N; Usui H; Tate S; Kawata T; Ito H
    Int J Gynecol Cancer; 2008; 18(1):80-4. PubMed ID: 17466053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined pretreatment with
    Ji S; Hu Q; Zhu J; Chen J; Chen Q; Liu Z; Shen C; Yang R; Sun H; Wu J; Gu K
    Trials; 2018 Aug; 19(1):416. PubMed ID: 30075736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia.
    Wakatsuki M; Kato S; Ohno T; Banu PA; Hoang NC; Yadamsuren E; Supriana N; Cao J; Devi CRB; Calaguas MJ; Chansilpa Y; Cho CK; Adylkhanov T; Okonogi N; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):183-189. PubMed ID: 31125594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer.
    Cheewakriangkrai C; Srisomboon J; Chitapanarux I; Suprasert P; Phongnarisorn C; Siriaree S; Charoenkwan K
    J Med Assoc Thai; 2005 Oct; 88(10):1331-7. PubMed ID: 16519375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.